TORONTO, May 12 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign) announced today the initiation of a short-term study of the UFIT®
biomedical system to determine the "best practices" for monitoring
blood pressure and blood glucose. The study is being conducted in
collaboration with McMaster University, which will use Biosign's
technology to benchmark a technology framework for providing reliable
and secure health information services.
To meet certain regulatory and market requirements, the study
("GAMUT-11") will involve several sites in various territories,
including Europe, Canada, USA, and China. The precision and accuracy of
UFIT® measurements will be further established, along with the
reliability and validity of monitoring, all in conformity with
internationally recognized standards. This additional UFIT® performance
data shall augment the existing data from the successful completion of
previous studies, including the year-long study conducted on diabetic
amputees by Algogene Pain Genetics in collaboration with The University
of Toronto Centre and The Centre for International Health.
"Biosign currently anticipates that the GAMUT study will be completed by
the end of 2011", stated Dr. Radu Leca, Biosign's Founder and CEO.
"Once we have completed this study, Biosign will be able to finalize
our UFIT regulatory filing strategy and related timing for the United
States and several other key markets."
UFIT® is Biosign's online system for recording and processing arterial
blood pressure signals, which are captured at the wrist through an
inflatable cuff. The system supports several medical measurements and
applications for monitoring common health conditions. The blood
pressure monitoring application (UFIT® TEN-10) has market clearances in
Canada and Europe. The application for blood pressure and blood glucose
monitoring (UFIT® TEN-20) has market clearance in Europe. As an online
device for the non-invasive measurement of blood pressure and glucose,
UFIT® TEN-20 should greatly simplify the way hypertension and diabetes
are evaluated and managed.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT® medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Biosign Contact Information
| Colley Clarke |
Phone: (416) 218-9800 ext. 234
| Alan S. Roemer |
The Trout Group
Phone: (646) 378-2945